FILTER

Refine your search with the following facets to narrow down your results.

5 Current news of Adocia

Adocia opens a subsidiary in the USA

09-Mar-2015 - Adocia announced the creation of a subsidiary in the USA, Adocia Incorporated, and the accompanying appointments of Simon Bruce, MD and Stephen Daly. Opening a US subsidiary is a key step in Adocia's strategy, the USA are currently the primary market for its productsTwo employees are already ...

appointments

Adocia is extending its intellectual property to new formulations of monoclonal antibodies

24-Oct-2012 - Adocia announced that it has filed another three patent applications covering new formulations of monoclonal antibodies. More specifically, these patent applications relate to original formulations that facilitate the subcutaneous administration of antibodies, as well as formulations that reduce ...

antibodies monoclonal antibodies patents

Adocia reports positive phase II clinical results for the treatment of diabetic foot ulcer

24-Apr-2012 - Adocia announced positive results from its Phase II clinical trial evaluating the safety and efficacy of BioChaperone(R) combined with PDGF-BB for the treatment of diabetic foot ulcer. This product has been compared with Regranex(R), a commercially available hydrogel of PDGF-BB (HealthPoint, ...

diabetic foot ulcers phase II studies

Adocia launches Phase IIa clinical study on type 1 diabetic patients with its fast-acting human insulin, HinsBet

28-Jun-2011 - Adocia SAS announced the launch of its second clinical trial for the development of HinsBet(R), its fast-acting human insulin.The company completed a Phase I study in March on healthy volunteers showing that the action of HinsBet(R) is as fast as that of NovoLog(R) and has less variability. The ...

diabetes insulin phase IIa studies

Adocia reports positive phase I clinical results on HinsBet, a fast-acting human insulin

18-Mar-2011 - Adocia, a privately-held biotechnology company specialized in regenerative medicine and in the treatment of chronic diseases, announced positive results from its phase I clinical study evaluating the safety and clinical utility of HinsBet(R), its fast-acting human insulin product for the ...

diabetes insulin phase I studies